StreetAlpha.app
Home › Stocks › IMTX

Immatics N.V. (IMTX)

Healthcare
$5.77
▼ −3.03%
LAST CLOSE · NOV 20

Immatics develops PRAME-targeted cancer treatments, including cell therapies and bispecific drugs, for patients with advanced cancers. It last closed at $5.77 on Nov 20, down 3.03% on the day. Over the last 12 months IMTX insiders bought $7.5M of stock on the open market and sold $139K, according to SEC Form 4 filings.

AI Auto Pilots
Is IMTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IMTX.

Key Stats

Last 12 months
Results
Net income
−EUR 196.4M
−1390.9% vs a year ago
Free cash flow
−EUR 183.2M
Balance sheet
Cash & equivalents
EUR 345.9M
At Dec 31
Shareholder equity
EUR 484.1M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −EUR 93.3M−EUR 93.3MFY2021FY2022: EUR 27.7MEUR 27.7MFY2022FY2023: −EUR 94.6M−EUR 94.6MFY2023FY2024: EUR 15.2MEUR 15.2MFY2024FY2025: −EUR 196.4M−EUR 196.4MFY2025

From IMTX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 5). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IMTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IMTX

Technical Analysis

IMTX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 15% below its 20 day and 28% below its 50 day average. It is 62% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $5.71, and the nearest resistance the Pivot at $5.81.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 7.5%/day
Key levels
$12.4152 week high+115.1%
$9.34200 day average+61.9%
$8.38100 day average+45.2%
$7.4050 day average+28.2%
$6.89Swing high (Nov 12)+19.4%
$6.6320 day average+14.9%
$5.91Pivot R1+2.4%
$5.81Pivot+0.7%
$5.77Last close
$5.7152 week low−1.0%
$5.67Pivot S1−1.7%
Indicators
RSI (14)29.28Oversold below 30Oversold
MACD-0.42Below its signal lineBearish
Stochastic6.6Near the bottom of its rangeOversold
ADX (14)24.7Weak trend
Williams %R-96.9Oversold below −80, overbought above −20Oversold
CCI (20)-132.0Oversold below −100, overbought above 100Oversold
Rate of change−9.3%Change over 10 sessionsBearish
ATR (14)$0.44Typical daily range, 7.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMTX

What happened before

See how IMTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IMTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IMTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IMTXHow many large options trades hit IMTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

IMTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲61 buying vs 35 selling
  • ▲Held by funds +8.4 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9184+8.3%
In funds' top 1000–
Held by funds82.9%74.4%+8.4 pts
New / increased22 / 3912 / 25+64.9%
Reduced / sold out21 / 1434 / 13−25.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IMTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$7.5M1 buy · 1 insider
Sold$139K1 sale · 1 insider
2026-08 bought $7.5M2026-11 sold $139KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 19Rainer KramerChief Business OfficerSale22,868$6.06$139K
Aug 26Perceptive Advisors LLCDirectorBuy863,060$8.69$7.5M
Every insider buy and sale for IMTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IMTX insider trades →

From SEC Form 4 filings by IMTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMTX is in one of them and how their past IMTX trades turned out.

IMTX in the AI portfolios
Loading…

IMTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMTX in an article yet. Here's the latest on the wider market.

IMTX in the news

About Immatics N.V.

Immatics is a biopharmaceutical company based in Tubingen, Germany, that develops cancer treatments aimed at PRAME, a protein found on the surface of many tumor cells. Its main products are T cell receptor therapies in two forms. Its cell therapies are made individually for each patient, while its bispecific drugs are made in advance and distributed through standard pharmaceutical supply channels. The treatments are intended for patients with advanced cancers, such as melanoma, and are given through specialized hospitals and medical centers.

Headquarters
Tubingen, Germany